Crosstown Fiber Expands Western Route, Addressing Chicago's Network Vulnerability Gap
ByAinvest
Tuesday, Oct 21, 2025 8:41 am ET1min read
ACAD--
Oppenheimer analyst Jay Olson has initiated coverage on iBio, Inc. (NASDAQ:IBIO) with an Outperform rating and a price target of $5. iBio shares closed at $0.8930 on Monday [1]. Keybanc analyst Justin Patterson has initiated coverage on Hims & Hers Health, Inc. (NYSE:HIMS) with a Sector Weight rating. Hims & Hers Health shares closed at $51.36 on Monday [1]. Johnson Rice analyst Martin Malloy has initiated coverage on Hyliion Holdings Corp. (AMEX:HYLN) with a Buy rating and a price target of $5. Hyliion Holdings shares closed at $2.13 on Monday [1]. Guggenheim analyst Jonathan Lee has initiated coverage on MARA Holdings, Inc. (NASDAQ:MARA) with a Neutral rating. MARA Holdings shares closed at $20.73 on Monday [1].
These analyst ratings provide valuable insights for investors, highlighting the potential growth opportunities and risks associated with these companies. It is essential for investors to conduct thorough research and consider their risk tolerance when making investment decisions.
HIMS--
HYLN--
IBIO--
Citigroup analyst Yigal Nochomovitz initiated coverage on ACADIA Pharmaceuticals with a Buy rating and a price target of $33. ACADIA Pharmaceuticals closed at $20.94 on Monday. This is one of the top 5 initiations for Tuesday. Oppenheimer analyst Jay Olson initiated coverage on iBio with an Outperform rating and a price target of $5. Keybanc analyst Justin Patterson initiated coverage on Hims & Hers Health with a Sector Weight rating. Johnson Rice analyst Martin Malloy initiated coverage on Hyliion Holdings with a Buy rating and a price target of $5. Guggenheim analyst Jonathan Lee initiated coverage on MARA Holdings with a Neutral rating.
Analysts have initiated coverage on several high-profile stocks, providing insights into their potential future performance. Citigroup analyst Yigal Nochomovitz has given ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a Buy rating with a price target of $33. The stock closed at $20.94 on Monday [1]. This positive outlook is one of the top 5 analyst initiations for Tuesday.Oppenheimer analyst Jay Olson has initiated coverage on iBio, Inc. (NASDAQ:IBIO) with an Outperform rating and a price target of $5. iBio shares closed at $0.8930 on Monday [1]. Keybanc analyst Justin Patterson has initiated coverage on Hims & Hers Health, Inc. (NYSE:HIMS) with a Sector Weight rating. Hims & Hers Health shares closed at $51.36 on Monday [1]. Johnson Rice analyst Martin Malloy has initiated coverage on Hyliion Holdings Corp. (AMEX:HYLN) with a Buy rating and a price target of $5. Hyliion Holdings shares closed at $2.13 on Monday [1]. Guggenheim analyst Jonathan Lee has initiated coverage on MARA Holdings, Inc. (NASDAQ:MARA) with a Neutral rating. MARA Holdings shares closed at $20.73 on Monday [1].
These analyst ratings provide valuable insights for investors, highlighting the potential growth opportunities and risks associated with these companies. It is essential for investors to conduct thorough research and consider their risk tolerance when making investment decisions.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet